Skip to main content
. 2009 Oct 5;3:109–127. doi: 10.4137/bbi.s3382

Table 6.

Sites selected by the MCFS as significant for resistance to Stavudine (NRTI). Only the top-scoring property is presented per site. Prevalence of mutations in the data and MCFS score are reported.

Rank Site Property Score Prevalence Status
1 P215 E oct-wat. 101.72 0.54 Known for NRTIs (abacavir, didanosine, stavudine, tenofovir, zidovudine) *
3 P210 isoel. point 82.64 0.26 Known for NRTIs (abacavir, stavudine, tenofovir, zidovudine) *
11 P67 vdW vol. 59.61 0.11 Known for NRTIs (abacavir, stavudine, tenofovir, zidovudine) *
14 P41 isoel. point 50.64 0.4 Known for NRTIs (abacavir, didanosine, stavudine, tenofovir, zidovudine) *
27 P151 vdW vol. 26.31 A0.04 Known for NRTIs (abacavir, didanosine, lamivudine, stavudine, zidovudine) *
29 P75 polarity 22.94 0.09 Known for NRTIs (stavudine) *
30 P208 isoel. point 22.44 0.1 Unknown +++
31 P118 freq. helix 22.24 0.17 Known but considered unimportant *
33 P44 E oct-wat. 21.59 0.1 Known for NRTIs (tenofovir) +
35 P69 E oct-wat. 21.02 0.15 Known for NRTIs (abacavir, didanosine, lamivudine, stavudine, tenofovir, zidovudine) *
47 P219 freq. turn 18.15 0.27 Known for NRTIs (didanosine, stavudine, zidovudine) *
48 P70 vdW vol. 17.83 0.28 Known for NRTIs (didanosine, stavudine, tenofovir, zidovudine) *
52 P116 polarity 16.93 0.03 Unknown +++
60 P43 freq. helix 15.78 0.14 Unknown +++
94 P218 freq. helix 8.31 0.08 Unknown +++
96 P228 isoel. point 7.83 0.14 Unknown +++
100 P203 freq. turn 7.45 0.12 Unknown +++
101 P122 vdW vol. 7.17 0.48 Unknown +++
103 P184 E sol. wat. 6.63 0.56 Known for NRTIs (abacavir, didanosine, lamivudine) +
110 P211 polarity 5.9 0.54 Unknown +++
111 P62 E sol. wat. 5.85 0.05 Part of the multi-nRTi resistance complex. Affects all NRTIs except Tenofovir *

Symbols represent the status of a site:

*

Sites known to contribute to resistance to Stavudine;

+

Sites where mutations are associated with resistance to some NRTI drugs but not to Stavudine;

++

Sites where mutations contribute to resistance to NNRTI drugs;

+++

Sites that are not included in the literature.5,6,30